Skip to content

Comparing Two Doses of a Nose Spray to Help Children Stay Still for MRI

A Prospective Observational Study on the Effects of Different Doses of Intranasal Dexmedetomidine for Pediatric Sedation in MRI - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/110413
Enrollment
80
Registered
2026-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R400- Somnolence Health Condition 2: G409- Epilepsy, unspecified Health Condition 3: Z018- Encounter for other specified special examinations Health Condition 4: R001- Bradycardia, unspecified Health Condition 5: T444- Poisoning by, adverse effect of and underdosing of predominantly alpha-adrenoreceptor agonists

Interventions

Control Intervention1: GROUP A: 2MCG/KG Intranasal Dexmedetomidine : GROUP A: 2MCG/KG Intranasal Dexmedetomidine Administered 30-45 Mins Prior to MRI via Intranasal Route Control Intervention2: GROUP

Sponsors

DR BHAKTI GHUDE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Paediatric patients aged 3-15years scheduled for magnetic resonance imaging. 2. ASA grade I and II patients. 3. Patients receiving intranasal dexmedetomidine as a part of routine premedication. 4. Parents providing informed consent.

Exclusion criteria

Exclusion criteria: . Parent/ guardian not willing to give consent. 2. Patients not receiving intranasal dexmedetomidine for premedication. 3. Patient with known allergic reactions to dexmedetomidine. 4. Patients with nasal pathologies like nasal septal abnormalities, nasal trauma, epistaxis, allergic rhinitis, nasal polyps and infections of upper respiratory tract. 5. Children requiring MRI on emergency basis. 6. Children with body mass index less than 18 and more than 28. 7. Patient with mental retardations, cerebral palsy, autism, uncorrected congenital heart disease.

Design outcomes

Primary

MeasureTime frame
sedation score assessed using the University of Michigan Sedation Scale(UMSS) The scoring system was as follows: 0 = Awake and alert 1 = Minimally sedated 2 = Moderately sedated 3 = Deeply sedated 4 = Unarousable Satisfactory sedation was defined as a UMSS score of 3 or more. Timepoint: During MRI procedure (30-45 minutes post drug administration)

Secondary

MeasureTime frame
Parental separation score o 1 = Calm o 2 = Anxious but reassurable o 3 = Anxious o 4 = Crying or resisting o Satisfactory parental separation was defined as a score of 2 or less Timepoint: at baseline;Mask acceptance score o 1 = Excellent o 2 = Good o 3 = Fair o 4 = Poor o Satisfactory mask acceptance was defined as a score of 2 or less Timepoint: at baseline;Rescue sedation requirement o Requirement of additional sedative medication due to inadequate sedation or excessive movement during MRI Timepoint: at 10mins,20mins,30mins, 40mins,50mins,60mins;MRI completion success o Successful completion of MRI without interruption or repeat scanning Timepoint: at 10mins, 20 mins,30mins,40 mins,50 mins,60 mins;Hemodynamic parameters o Heart rate o Blood pressure o Respiratory rate o Oxygen saturation Timepoint: at baseline,10mins, 20 mins,30mins,40 mins,50 mins,60 mins;Adverse events o Bradycardia o Hypotension o Respiratory depression o Oxygen desaturation Timepoint: at baseline,10mins, 20 mins,30mins,40 mins,50 mins,60 mins

Countries

India

Contacts

Public ContactDR Bhakti Ghude

Lokmanya Tilak Municipal Medical College and Hospital

shantanu71270@gmail.com9869100774

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026